Here, we describe a novel interplay between SPG11 and IFNγ response, provide insights into cell-intrinsic and cell-extrinsic mechanisms, and introduce CNS immune cells as a potential therapeutic target in SPG11–HSP patients. Here, SPG11 is linked to hereditary spastic paraplegia.